Literature DB >> 6895973

In vitro and In vivo evaluations of a tableted antacid and sucralfate, a new antiulcer agent.

B F McGraw, E J Hesterlee, F L Lanza, M A Tesler.   

Abstract

Sucralfate is a nonsystemic drug used in the therapy of peptic ulcer disease. It is an aluminum salt of a sulfated disaccharide which adheres to ulcerated sites and forms a cytoprotective barrier to acid peptic digestion. The purposes of this study were to determine whether sucralfate had antacid activity in humans and to test the validity of the in vitro antacid qualifying test by comparing its results for tableted products with those of in vivo studies. In the in vitro antacid qualifying test Maalox #1 (4 tablets) passes and sucralfate (1 gm.) failed. These findings were consistent with the results of in vivo tests utilizing a telemetric device, the Heidelberg capsule and tube aspirations. We conclude that sucralfate does not possess antacid properties and that the results of the standard in vitro antacid qualifying test correlated well with those of in vitro studies.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6895973

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  2 in total

1.  Effects of ranitidine and sucralfate on ketoconazole bioavailability.

Authors:  S C Piscitelli; T F Goss; J H Wilton; D T D'Andrea; H Goldstein; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

Review 2.  Sucralfate. A review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.